Insurers omit coverage for new RSV vaccines, sparking out-of-pocket costs

Newly approved vaccines for respiratory syncytial virus (RSV) are not being covered by certain insurance plans, compelling individuals to shoulder out-of-pocket costs upwards of $300, reports The New York Times. The FDA-endorsed RSV vaccines, developed for adults 60 and older, are seen as pivotal, with RSV accounting for 6,000-10,000 deaths annually in the United States among those over 65.